{"filing":{"accession_number":"0001104659-26-064514","cik":"0001477845","ticker":"ANVS","company_name":"Annovis Bio, Inc.","form":"8-K","filing_date":"2026-05-20","report_date":null,"primary_document":"tm2615162d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465926064514/tm2615162d1_8k.htm"},"events":[{"id":9736,"run_id":8534,"accession_number":"0001104659-26-064514","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Annovis Bio entered into an Underwriting Agreement on May 20, 2026 to issue 7,895,000 shares of common stock and 7,105,500 warrants in a public offering expected to raise approximately $15 million in gross proceeds, with net proceeds to be used for clinical development and working capital.","company_name":"Annovis Bio, Inc.","ticker":"ANVS","filing_date":"2026-05-20","form":"8-K","submitted_at":null,"items":[{"id":520,"accession_number":"0001104659-26-064514","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Annovis Bio entered into an Underwriting Agreement on May 20, 2026 to issue 7,895,000 shares of common stock and 7,105,500 warrants in a public offering expected to raise approximately $15 million in gross proceeds. This is a material dilutive equity issuance disclosed under Item 1.01, with the company planning to use net proceeds for clinical development and working capital—a typical capital raise by a biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:42:58.800944+00:00","company_name":"","ticker":null,"filing_date":""},{"id":521,"accession_number":"0001104659-26-064514","item_number":"7.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces the launch and pricing of an \"Offering\" via press releases on May 19-20, 2026. While the Item 7.01 filing itself does not specify the offering type, the context of a public company announcing an offering launch and pricing strongly suggests a capital raise (likely equity or convertible securities). Such offerings are material to investors as they affect ownership dilution and the company's capital structure. The high confidence reflects the clear language around \"launch\" and \"pricing\" of an offering, though the specific instrument type is not explicitly stated in this excerpt.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:42:58.800944+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":520,"accession_number":"0001104659-26-064514","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Annovis Bio entered into an Underwriting Agreement on May 20, 2026 to issue 7,895,000 shares of common stock and 7,105,500 warrants in a public offering expected to raise approximately $15 million in gross proceeds. This is a material dilutive equity issuance disclosed under Item 1.01, with the company planning to use net proceeds for clinical development and working capital—a typical capital raise by a biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:42:58.800944+00:00","company_name":"Annovis Bio, Inc.","ticker":"ANVS","filing_date":"2026-05-20"},{"id":521,"accession_number":"0001104659-26-064514","item_number":"7.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces the launch and pricing of an \"Offering\" via press releases on May 19-20, 2026. While the Item 7.01 filing itself does not specify the offering type, the context of a public company announcing an offering launch and pricing strongly suggests a capital raise (likely equity or convertible securities). Such offerings are material to investors as they affect ownership dilution and the company's capital structure. The high confidence reflects the clear language around \"launch\" and \"pricing\" of an offering, though the specific instrument type is not explicitly stated in this excerpt.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:42:58.800944+00:00","company_name":"Annovis Bio, Inc.","ticker":"ANVS","filing_date":"2026-05-20"}]}